Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody

Stephen Kennel, Trish Lankford, Kathryn M. Flynn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Syngeneic monoclonal antibodies (MoAb) to Moloney sarcoma cells (MSC) were produced by fusion of spleen cells from MSC regressor mice to myeloma SP2/0. MoAb 244-19A, an immunoglobulin G2b, bound to MSC cells and did not bind to two other sarcomas (K-BALB and Ha2), a carcinoma (Line 1), a fibroblast (A31) or a fibroblast infected with C-type virus (A31-Moloney leukemia virus). In contrast, MoAb 271-1A bound to the MSC and Ha2 sarcoma and line 1 carcinoma as well as to the normal and infected fibroblast cultures. Antibodies were tested for therapeutic effect using three schedules of antibody injection. Injection i.p. of ascites fluid containing 244-19A MoAb given on Days-1, 0, and +1 relative to tumor cell injection increased life span significantly over that of control animals given injections (P3, immunoglobulin G, or MoAb 271-1A) and produced some seven of 19, one of five, and one of five long-term survivors in three separate experiments. Antibody given to animals with established tumors (4 days after implantation) also prolonged life span significantly and produced three of nine long-term survivors. Antibody given to animals with very large tumor burdens (10 days after implantation) did not prolong life span significantly. Optimal dose, schedule, and mechanism studies concerning this therapy are in progress.

Original languageEnglish (US)
Pages (from-to)2843-2848
Number of pages6
JournalCancer Research
Volume43
Issue number6
StatePublished - Jun 1 1983

Fingerprint

Sarcoma
Monoclonal Antibodies
Injections
Antibodies
Fibroblasts
Survivors
Appointments and Schedules
Therapeutics
Moloney murine leukemia virus
Carcinoma
Cell Fusion
Therapeutic Uses
Tumor Burden
Ascites
Immunoglobulins
Neoplasms
Spleen
Immunoglobulin G
Viruses

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kennel, S., Lankford, T., & Flynn, K. M. (1983). Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody. Cancer Research, 43(6), 2843-2848.

Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody. / Kennel, Stephen; Lankford, Trish; Flynn, Kathryn M.

In: Cancer Research, Vol. 43, No. 6, 01.06.1983, p. 2843-2848.

Research output: Contribution to journalArticle

Kennel, S, Lankford, T & Flynn, KM 1983, 'Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody', Cancer Research, vol. 43, no. 6, pp. 2843-2848.
Kennel, Stephen ; Lankford, Trish ; Flynn, Kathryn M. / Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody. In: Cancer Research. 1983 ; Vol. 43, No. 6. pp. 2843-2848.
@article{012d528e2aa345e9aa961b2b72bc117c,
title = "Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody",
abstract = "Syngeneic monoclonal antibodies (MoAb) to Moloney sarcoma cells (MSC) were produced by fusion of spleen cells from MSC regressor mice to myeloma SP2/0. MoAb 244-19A, an immunoglobulin G2b, bound to MSC cells and did not bind to two other sarcomas (K-BALB and Ha2), a carcinoma (Line 1), a fibroblast (A31) or a fibroblast infected with C-type virus (A31-Moloney leukemia virus). In contrast, MoAb 271-1A bound to the MSC and Ha2 sarcoma and line 1 carcinoma as well as to the normal and infected fibroblast cultures. Antibodies were tested for therapeutic effect using three schedules of antibody injection. Injection i.p. of ascites fluid containing 244-19A MoAb given on Days-1, 0, and +1 relative to tumor cell injection increased life span significantly over that of control animals given injections (P3, immunoglobulin G, or MoAb 271-1A) and produced some seven of 19, one of five, and one of five long-term survivors in three separate experiments. Antibody given to animals with established tumors (4 days after implantation) also prolonged life span significantly and produced three of nine long-term survivors. Antibody given to animals with very large tumor burdens (10 days after implantation) did not prolong life span significantly. Optimal dose, schedule, and mechanism studies concerning this therapy are in progress.",
author = "Stephen Kennel and Trish Lankford and Flynn, {Kathryn M.}",
year = "1983",
month = "6",
day = "1",
language = "English (US)",
volume = "43",
pages = "2843--2848",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Therapy of a Murine Sarcoma Using Syngeneic Monoclonal Antibody

AU - Kennel, Stephen

AU - Lankford, Trish

AU - Flynn, Kathryn M.

PY - 1983/6/1

Y1 - 1983/6/1

N2 - Syngeneic monoclonal antibodies (MoAb) to Moloney sarcoma cells (MSC) were produced by fusion of spleen cells from MSC regressor mice to myeloma SP2/0. MoAb 244-19A, an immunoglobulin G2b, bound to MSC cells and did not bind to two other sarcomas (K-BALB and Ha2), a carcinoma (Line 1), a fibroblast (A31) or a fibroblast infected with C-type virus (A31-Moloney leukemia virus). In contrast, MoAb 271-1A bound to the MSC and Ha2 sarcoma and line 1 carcinoma as well as to the normal and infected fibroblast cultures. Antibodies were tested for therapeutic effect using three schedules of antibody injection. Injection i.p. of ascites fluid containing 244-19A MoAb given on Days-1, 0, and +1 relative to tumor cell injection increased life span significantly over that of control animals given injections (P3, immunoglobulin G, or MoAb 271-1A) and produced some seven of 19, one of five, and one of five long-term survivors in three separate experiments. Antibody given to animals with established tumors (4 days after implantation) also prolonged life span significantly and produced three of nine long-term survivors. Antibody given to animals with very large tumor burdens (10 days after implantation) did not prolong life span significantly. Optimal dose, schedule, and mechanism studies concerning this therapy are in progress.

AB - Syngeneic monoclonal antibodies (MoAb) to Moloney sarcoma cells (MSC) were produced by fusion of spleen cells from MSC regressor mice to myeloma SP2/0. MoAb 244-19A, an immunoglobulin G2b, bound to MSC cells and did not bind to two other sarcomas (K-BALB and Ha2), a carcinoma (Line 1), a fibroblast (A31) or a fibroblast infected with C-type virus (A31-Moloney leukemia virus). In contrast, MoAb 271-1A bound to the MSC and Ha2 sarcoma and line 1 carcinoma as well as to the normal and infected fibroblast cultures. Antibodies were tested for therapeutic effect using three schedules of antibody injection. Injection i.p. of ascites fluid containing 244-19A MoAb given on Days-1, 0, and +1 relative to tumor cell injection increased life span significantly over that of control animals given injections (P3, immunoglobulin G, or MoAb 271-1A) and produced some seven of 19, one of five, and one of five long-term survivors in three separate experiments. Antibody given to animals with established tumors (4 days after implantation) also prolonged life span significantly and produced three of nine long-term survivors. Antibody given to animals with very large tumor burdens (10 days after implantation) did not prolong life span significantly. Optimal dose, schedule, and mechanism studies concerning this therapy are in progress.

UR - http://www.scopus.com/inward/record.url?scp=0020532321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020532321&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 2843

EP - 2848

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -